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The modulation of adult neuroplasticity is involved in the
mood-improving actions of atypical antipsychotics in an
animal model of depression
M Morais1,2, P Patrício1,2, A Mateus-Pinheiro1,2, ND Alves1,2, AR Machado-Santos1,2, JS Correia1,2, J Pereira1,2, L Pinto1,2, N Sousa1,2 and
JM Bessa1,2
Depression is a prevalent psychiatric disorder with an increasing impact in global public health. However, a large proportion of
patients treated with currently available antidepressant drugs fail to achieve remission. Recently, antipsychotic drugs have received
approval for the treatment of antidepressant-resistant forms of major depression. The modulation of adult neuroplasticity, namely
hippocampal neurogenesis and neuronal remodeling, has been considered to have a key role in the therapeutic effects of
antidepressants. However, the impact of antipsychotic drugs on these neuroplastic mechanisms remains largely unexplored. In this
study, an unpredictable chronic mild stress protocol was used to induce a depressive-like phenotype in rats. In the last 3 weeks of
stress exposure, animals were treated with two different antipsychotics: haloperidol (a classical antipsychotic) and clozapine (an
atypical antipsychotic). We demonstrated that clozapine improved both measures of depressive-like behavior (behavior despair and
anhedonia), whereas haloperidol aggravated learned helplessness in the forced-swimming test and behavior ﬂexibility in a
cognitive task. Importantly, an upregulation of adult neurogenesis and neuronal survival was observed in animals treated with
clozapine, whereas haloperidol promoted a downregulation of these processes. Furthermore, clozapine was able to re-establish the
stress-induced impairments in neuronal structure and gene expression in the hippocampus and prefrontal cortex. These results
demonstrate the modulation of adult neuroplasticity by antipsychotics in an animal model of depression, revealing that the atypical
antipsychotic drug clozapine reverts the behavioral effects of chronic stress by improving adult neurogenesis, cell survival and
neuronal reorganization.
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INTRODUCTION
Major depression is a highly prevalent and complex psychiatric
disorder that affects multiple behavioral domains, presenting a
wide range of symptoms, namely depressed mood, anhedonia,
anxiety and cognitive impairments that confer a severe disability
and impaired quality of life in patients.1–3 Strikingly, up to 60% of
patients treated with the currently available therapies do not
achieve full remission and evolve to treatment resistance.4,5 Taking
this into account, it is essential to explore new strategies to achieve
full remission and to prevent the recurrence of depressive episodes.
Multiple clinical studies have previously highlighted the potential
beneﬁcial effects of atypical antipsychotics in treatment-resistant
depression.6–8 In accordance, different atypical antipsychotic drugs
have received approval from the Food and Drug Administration
(FDA) for the treatment of antidepressant-resistant forms of major
depression (either as monotherapy or augmentation),9 a fact that
supports their potential role in the emotional domain. Studies in
animals conﬁrm this view and show that the association of an
atypical antipsychotic and a selective serotonin reuptake inhibitor
synergistically increases the release of dopamine in prefrontal areas,
thus improving motivation, pleasure and appetite.10,11 However,
until now the mechanisms by which atypical antipsychotics work in
the treatment of this disorder remains unclear.
Antipsychotic drugs are generally classiﬁed into classical and
atypical. The mechanism of action of classical antipsychotics (for
example, haloperidol), is based on dopamine receptor type 2 (D2)
antagonism and have proven to be effective in the positive
symptoms of schizophrenia. However, besides eliciting extrapyr-
amidal symptoms (EPS), hyperprolactinemia and metabolic
changes, these drugs may exacerbate the negative and cognitive
symptoms. In contrast, second generation antipsychotics also
known as atypical antipsychotics (for example, clozapine), with
less potent D2 antagonism and with modulation of serotonin and
noradrenaline receptors, maintain their effectiveness against
positive symptoms, with fewer EPS and with no impairments on
cognitive function and negative symptoms.12,13
Adult neuroplasticity, namely hippocampal neurogenesis and
neuronal morphology have been implicated in the action of
antidepressants.14–18 This hypothesis is supported by animal and
human studies describing a downregulation of hippocampal
neurogenesis and neuronal morphological complexity under
stressful conditions, which is reverted by antidepressant
drugs.16,19–21 Furthermore, these neuroplastic changes have been
associated with the expression of neurotrophic factors, cell adhesion
molecules and synaptic proteins.17,22–24 However, the importance
of these mechanisms in the therapeutic effects of antipsychotics
in depression has never been explored.
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In the present study, we evaluated the behavioral effects of
different classes of antipsychotics in the chronic mild stress (CMS)
animal model of depression. Rats were exposed to the CMS
paradigm for 7 weeks to induce core symptoms of depressive-like
behavior.22,25 During the last 3 weeks of CMS, two different
antipsychotic drugs, haloperidol and clozapine, were daily
administered. Anhedonia was assessed using the sucrose pre-
ference test (SPT), during the experimental protocol. Behavior
despair was evaluated with the forced-swimming test (FST).
Cognitive function was assessed by different tasks designed to
assess spatial working, reference memory and behavioral ﬂex-
ibility. To explore adult neuroplasticity, we examined whether
stress-induced changes in neurogenesis at short-term16,22 and
long-term26 are inﬂuenced by the different classes of antipsycho-
tic drugs. Furthermore, dendritic arborization and complexity was
analyzed in Golgi-impregnated neurons in the hippocampus and
prefrontal cortex (PFC). Finally, the expression of genes involved in
neuroplasticity and in antipsychotic action was evaluated in these
brain regions.
MATERIALS AND METHODS
Animals
Male Wistar rats (n=79, Charles-River Laboratories, L'Arbresle, France),
weighing 200–300 g and with 3 months of age were group-housed (three
per cage) under 12h light:12h dark cycles, at 22 °C, relative humidity of
55% and with food and water ad libitum. These animals were randomly
assigned to four main experimental groups—a control group without
stress exposure treated with saline (n= 17) and four groups exposed to
CMS and treated with either saline (n=17), haloperidol (0.05 mg kg− 1,
n= 15), clozapine (2.5 mg kg− 1, n=15) and ﬂuoxetine (10 mg kg− 1, n= 15).
A preliminary behavioral study to determine the ideal dosages of the
antipsychotics was conducted using three different dosages of haloperidol
(0.025 mg kg− 1, n= 6; 0.05 mg kg− 1, n= 6; 0.075 mg kg− 1, n= 6) and
clozapine (1 mg kg− 1, n= 6; 2.5 mg kg− 1, n=6; 5 mg kg− 1, n=6). All
procedures were carried out in accordance with European Union Directive
86/609/EEC and NIH guidelines on animal care and experimentation.
Chronic mild stress protocol
Chronic mild stress was implemented based on a slightly modiﬁed
protocol,27 already validated in our laboratory.22 Brieﬂy, the animals were
random- and uninterruptedly exposed to a variety of mild stressors
(conﬁnement to a restricted space for 1h; overnight food deprivation
followed by 1 h of exposure to inaccessible food; overnight water
deprivation followed by 1h of exposure to an empty bottle; overnight
damp bedding; inverted light/dark cycles; exposure to stroboscopic lights
during 1 h and noise exposure during 1h during 7 weeks. During the last
3 weeks of CMS, animals were given daily injections of saline, haloperidol,
clozapine and ﬂuoxetine.
Drugs
The antipsychotics used in this study were haloperidol (0.05 mg kg− 1;
Sigma-Aldrich, St Louis, MO, USA), clozapine (2.5 mg kg− 1; Kemprotec,
Middlesborough, UK) and ﬂuoxetine (10 mg kg− 1; Kemprotec). Com-
pounds were dissolved in distilled water and administered intraperitone-
ally (i.p.) (ml kg− 1) during the last 3 weeks of the CMS protocol. All
injections were performed at 1800 hours. To assess cell proliferation,
neurogenesis and gliogenesis all animals received an injection of
bromodeoxyuridine (BrdU) (100 mg kg− 1, i.p.) 24 h before killed. To assess
cell and neuronal survival all the animals were injected with BrdU
(50 mg kg− 1 day− 1, i.p) during 5 days and killed 1 month later.
Behavioral tests
Sucrose preference test. To assess anhedonia, the SPT was conducted
weekly during all the experimental procedure. Brieﬂy, animals were
allowed to habituate to the sucrose solution for 1 week before the CMS
protocol to establish baseline values for sucrose preference. To test sucrose
preference, animals that were subjected to food and water deprivation for
24 h and then presented with two pre-weighed bottles containing 2% of
sucrose solution or tap water for a period of 1h. Sucrose preference was
calculated according to the formula: sucrose preference= (sucrose intake/
(sucrose intake + water intake)) × 100, as previously described.22 Anhedo-
nia was deﬁned as a reduction in sucrose preference relative to baseline
levels.
Forced swimming test. Behavior despair was assessed through the FST on
the last day of exposure to CMS. Twenty-four hours after a pre-test session
(10 min), the FST was conducted by placing rats in cylinders ﬁlled with
water (25 °C; depth 30 cm) for a period of 5 min. Test sessions were
assessed using a camera connected to a video tracking system (Viewpoint,
Lyon, France); the system automatically calculated immobility time and
latency to immobility. Behavior despair was deﬁned as an increase in time
of immobility and a decrease in latency to immobility.
Morris water maze. Cognitive function was evaluated in different tasks of
the Morris water maze (MWM): spatial working, reference memory and
behavioral ﬂexibility. The MWM was conducted in a circular black tank
(diameter: 170 cm; depth: 50 cm), divided in quadrants by imaginary lines,
and ﬁlled with water (22 °C) to a depth of 31 cm. During testing, a black
platform (12 × 12 cm; invisible to the rats) was placed at a height of 30 cm.
The room was dimly lit and extrinsic visual clues were glued to the walls.
Data were collected using a video tracking system (Viewpoint).28
The working memory task was used to evaluate the cognitive domain
that relies on the interplay between the hippocampal and PFC function.28
In this task, the position of the platform is kept constant during the four
trials of each day, but varies on each successive day such that all four
quadrants are used. Rats are placed, facing the wall of the maze, at a
different starting point (north, east, south or west) at the beginning of each
of the four daily trials. A trial is considered complete when the rat escapes
onto the platform; when this escape fails to occur within 120 s, the animal
is gently guided to the platform and an escape latency of 120 s is recorded
for that trial. Rats are allowed to spend 30s on the escape platform before
being positioned at a new starting point. Length of the path described
(distance swam) and time spent to reach the platform (escape latency) are
recorded in the consecutive trials.
After the working memory procedure, animals were tested in the spatial
learning test, an hippocampal-dependent task. In this task, animals were
tested for three consecutive days (four trials per day, with a maximum of
2 min per trial). The escape platform was placed in the center of an
arbitrarily-deﬁned quadrant, assigned to a speciﬁc test subject. Test
sessions begun with rats being placed, facing the wall of the maze, in a
deﬁned start position and ﬁnished once the escape platform had been
reached. This procedure was continued in a clock-wise fashion over the
subsequent trials. The distance traveled and the time spent to reach the
platform was recorded. When the escape platform was not reached within
2 min, the experimenter guided the animal to the platform. At the end of
each test session, animals were dried and allowed to rest for 30 s before
being returned to the maze for the remaining test sessions of that day.
After the reference memory evaluation, animals were tested in a reverse
learning task (a PFC-dependent function) in which the escape platform was
positioned in a new (opposite) quadrant and rats were tested in a four-trial
paradigm, as described above. For this task, distance and time spent
swimming in each quadrant were recorded. The difference between
distances traveled in the quadrant containing the newly-positioned
platform (‘new’) and the quadrant that previously contained the platform
(‘old’) was calculated as a measure of reversal performance. The total
distance swum was evaluated as a measure of locomotor activity. All
behavior data analysis was performed with the experimenter blinded to
the group under analysis.
Open ﬁeld test. Locomotor activity was investigated using the open-ﬁeld
test in a room brightly illuminated by white light. Brieﬂy, rats were placed
in the center of an arena (43.2 × 43.2 cm2, transparent acrylic walls and
white ﬂoor, MedAssociates, St Albans, VT, USA) and instant position was
monitored online over a period of 5 min with the aid of two 16-beam
infrared arrays. Total distance traveled was used as a measure of locomotor
activity.
Tissue processing and immunohistochemical analysis. Animals were deeply
anaesthetized with sodium pentobarbital (20%; Eutasil, Safoni) and
perfused with saline and rapidly decapitated. Serial coronal sections
(20 μm) were cut on a cryostat and stored at − 20 ºC. For the short-term
analysis, we evaluate the impact of antipsychotics immediately after
chronic treatment on cell proliferation by counting the total number of
BrdU+ cells (1:100, Abcam, Cambridge, UK) in the hippocampus using
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Olympus BX51 optical microscope and Newcast software (Visiopharm,
Hoersholm, Denmark). BrdU is incorporated into DNA during the S-phase
of the mitotic process, thus allowing the assessment of cell proliferation.
For hippocampal analysis the densities were estimated in the subgranular
zone of the dentate gyrus. To assess the impact of these drugs on
hippocampal neurogenesis and gliogenesis, we performed a double
staining for BrdU and polysialylated neuronal cell adhesion molecule (PSA-
NCAM) (for neuroblasts; 1:200; Millipore, Billerica, MA, USA) and glial
ﬁbrillary acidic protein (GFAP) (for glia; 1:200; Sigma-Aldrich, St. Louis, MO,
USA) using a confocal microscope (Olympus FV1000). For the long-term
analysis, we counted the number of BrdU+ cells that survived 4 weeks later
after the last BrdU injection and the neuronal phenotype (NeuN, for
mature neurons; 1:100; Chemicon, Temecula, CA, USA) of these cells. The
schematic representation of the experimental design is described in
Figure 1a. To minimize bias, each slide was coded to keep the
experimenter blind to the experimental group.
Neuronal morphology. Three-dimensional morphometric analysis was
performed on Golgi-Cox stained material obtained from rats that had
been transcardially perfused with 0.9% saline and further processed, as
previously described.22 For each animal, at least eight neurons (randomly
selected) were analyzed in the hippocampal dentate gyrus and PFC. For
each selected neuron, dendritic branches were reconstructed at × 1000
(oil) magniﬁcation (×100 objective × × 10 ocular) using a motorized micro-
scope (Axioplan 2; Carl Zeiss, Oberkochen, Germany) and the Neurolucida
software (MBF Bioscience, Williston, VT, USA). Three-dimensional analysis of
the reconstructed neurons was performed using the NeuroExplorer
software (MBF Bioscience). Measurements from individual neurons from
each animal were averaged. Total dendritic length was compared among
the experimental groups. Branching of the neurons was evaluated using
3D Sholl analysis; for this, the number of dendritic intersections with
concentric circles positioned at radial intervals of 20 μm was determined.
To minimize bias, each slide was coded to keep the experimenter blind to
the experimental group.
Gene expression. Total RNA was isolated from hippocampus and PFC
using Trizol reagent (Invitrogen, Carlsbad, CA, USA). A total of 500 ng of
total RNA was reverse-transcribed using qScript cDNA SuperMix (Quanta
Biosciences, Gaithersburg, MD, USA). Quantitative real-time PCR analysis
was used to measure the expression levels of the neural cell adhesion
Figure 1. Behavioral effects of the chronic mild stress (CMS) and antipsychotic treatment on mood and cognition. (a) CMS protocol was
applied to the rats for 7 weeks; two different antipsychotics (haloperidol and clozapine) were administrated in the last 3 weeks of the CMS
protocol. To analyze the impact of antipsychotics on cell proliferation, we injected BrdU 24 h before killed (short-term effects). To analyze the
impact on neuronal survival, we injected BrdU during 5 days, the killing was performed 4 weeks later (long-term effects). Animals used for
morphological and gene expression analysis were killed immediately after performing the behavior analysis. (b) Sucrose preference test was
performed during all experimental protocol to evaluate anhedonia. Continuous and discontinuous lines represent repeated measures ANOVA
(time× treatment) and one-way ANOVA (in the week 7), respectively. (c) Learned helplessness was evaluated in the forced swim test (FST).
Cognition was analyzed in the different tasks of the Morris water maze (MWM) (d) working memory (e) spatial learning task and (f) behavior
ﬂexibility. Data represented as mean+s.e.m. #Denotes the effect of CMS-exposure; *denotes the effect of antipsychotic compared with CMS
non-treated animals. *Po0.05; **,##Po0.01; ***Po0.001. n= 15–17 animals per group.
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molecule 1 (Ncam1), synapsin 1 (Syn1) and brain-derived neurotrophic
factor (BDNF) in the hippocampus and PFC. In the PFC, we also analyzed
gene expression levels of different dopamine receptors (Drd1, Drd2 and
Drd3). Target gene expression levels were normalized against the
housekeeping gene Beta-2-Microglobulin (B2M). Sense and antisense
sequences can be found in Supplementary Table S1. Reactions were
performed in an Applied Biosystems 7500 Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) using PerfeCTa SYBRGreen
SuperMix, Low ROX (Quanta Biosciences). The relative expression was
calculated using the DDCt method. Results are presented as fold-change of
mRNA levels between the respective experimental groups after normal-
ization to B2M levels.
Statistical analysis
Adequate sample size was determined a priori using G-Power software
v3.1.9.2 (SPSS, Chicago, IL, USA), based on results of a previous pilot
experiment suggesting a η2p of 0.424 for the effect of treatment in the FST
and assuming a 95% power and 5% probability of type I errors. After
conﬁrming the homogeneity of the data distribution, the appropriate
statistical tests were performed using SPSS software. Equality of variances
was tested with an F test. Repeated measures ANOVA was used to analyze
the results of SPT, reference memory, working memory and sholl analysis.
Paired sample t-test was used to analyze behavioral ﬂexibility. One-way
ANOVA was used to evaluate the impact of CMS and antipsychotic
treatment in each week of the SPT (Bonferroni corrected), FST, neuronal
morphology, gene expression and immunostaining results. Differences
between groups were then determined by Tukey’s honestly signiﬁcant
difference test (Tukey HSD) post hoc analysis. All values were calculated as
means+standard error of the mean (s.e.m.). Statistical signiﬁcance was
accepted for Po0.05.
RESULTS
Behavioral results
Anhedonia was assessed weekly in the sucrose preference test.
Analysis of the test during the ﬁrst 4 weeks of the CMS protocol
revealed a signiﬁcant decrease of sucrose preference in animals
exposed to chronic stress (F1, 62 = 17.470; Po0.001, Figure 1b)
conﬁrming the induction of an anhedonic behavioral phenotype.
During the last 3 weeks of the CMS protocol, a signiﬁcant global
effect of treatment was observed (F2,44 = 3.378; P= 0.043,
Figure 1b). Post hoc analysis revealed signiﬁcant differences
between animals treated with vehicle and animals treated with
clozapine (P= 0.034) with no signiﬁcant differences when com-
pared with haloperidol-treated animals (P= 0.344) (Figure 1b). The
analysis of the effect of treatment in each time point of the SPT
(week 4, 5, 6 and 7) revealed a signiﬁcant effect at week 7 that
survived to multiple comparisons (Bonferroni) (F2,44 = 15.818;
Po0.001), with post hoc analysis revealing signiﬁcant differences
between animals treated with vehicle and animals treated with
clozapine (Po0.001) and haloperidol (Po0.001).
CMS also induced increased immobility in the FST
(F1,32 = 11.390; P= 0.002, Figure 1c), a measure of behavioral
despair, which is another hallmark symptom of depressive-like
behavior. The chronic treatment with antipsychotics induces an
overall effect (F2,44 = 12.249; Po0.001, Figure 1c). Treatment with
clozapine reversed the stress-induced behavior in the immobility
time (P= 0.037). In haloperidol-treated animals, we observed an
increase in the immobility time compared to CMS animals
(P= 0.037, Figure 1c), indicating an aggravation of the
depressive-like phenotype.
Cognitive function was assessed in the different tasks of the
MWM. In the working memory task, we observed no differences
between all the groups analyzed (Figure 1d).
The evaluation of spatial learning in the MWM also failed to
reveal any signiﬁcant differences between control and CMS
animals (F1,32 = 0.015; P= 0.902, Figure 1e). Accordingly, neither
clozapine nor haloperidol-induced changes in performance in the
spatial learning task in the MWM. On the other hand, performance
in the reverse learning task, to test behavior ﬂexibility, was
signiﬁcantly impaired in animals exposed to CMS, as indicated by
the lower percentage of distance swum in the ‘new’ quadrant
compared with the percentage spent in the ‘old’ quadrant
(t16 = 2.637; P= 0.018, Figure 1f). This impairment was reversed
by clozapine treatment with animals spending approximately the
same time in ‘old’ and ‘new’ quadrant as the control group
(t16 = 0.990; P= 0.076, Figure 1f). The chronic treatment with
haloperidol was not able to reverse the impairment induced by
CMS-exposure (t14 =6.484; Po0.001).
We analyzed the behavioral effects of the different dosages of
antipsychotics in the FST and sucrose preference test. The
intermediate dosages of haloperidol (0.05 mg kg−1) and clozapine
(2.5 mg kg− 1) displayed the most favorable effects in anhedonic
behavior in the sucrose preference test and were therefore used in
this study (Supplementary Figure S1). We also treated a subset of
animals with the antidepressant drug ﬂuoxetine. As expected,
ﬂuoxetine treatment was able to reverse the negative effects
induced by the exposition to the CMS protocol (Supplementary
Figure S2). In addition, we analyzed the impact of antipsychotic
drugs in control animals (Supplementary Figure S3); we found no
differences between groups, indicating that the chronic treatment
with antipsychotics in control animals does not induce signiﬁcant
changes in all the behavior domains analyzed. The open ﬁeld test
was performed to analyze locomotor activity. We found no
differences in the distance traveled between all the groups under
analysis (Supplementary Figure S4).
Cell proliferation and differentiation
The possible modulation of adult hippocampal neurogenesis by
CMS and antipsychotic treatment was analyzed in two different
time points—immediately after the chronic treatment (‘short-
term’) and 4 weeks after the cessation of chronic treatment (‘long-
term’). We ﬁrst analyzed the short-term effects on hippocampal
cell proliferation by determining the number of BrdU-labeled cells
per area in the subgranular zone of the dentate gyrus (DG). The
density of BrdU+ cells was signiﬁcantly reduced in animals
exposed to CMS (F1,8 = 11.033, P= 0.011, Figures 1a and b).
Chronic treatment with different classes of antipsychotics had a
different impact on cell proliferation (F1,12 = 10.737, P= 0,002,
Figure 1b). Treatment with clozapine promoted an increase in cell
proliferation (P= 0.004, Figure 1b), whereas haloperidol had no
effect (P= 0.983, Figure 1b). To determine the cell fate of the
BrdU+ cells, we co-labeled these cells with cell-speciﬁc markers,
including PSA-NCAM and GFAP to assess neurogenesis and
astrogliogenesis, respectively. In the case of neurogenesis, the
percentage of BrdU+ cells that co-labeled with PSA-NCAM was
signiﬁcantly reduced (F1,8 = 9.436; P= 0.015, Figures 1c and d) in
rats exposed to CMS. Regarding the effect of chronic treatment
with antipsychotics, an overall effect was observed (F2,12 = 17.011;
Po0.001, Figure 1d); with clozapine-treated animals presenting
an increase (P= 0.001, Figure 1d) in the levels of neurogenesis and
with no effect in the haloperidol-treated group (P= 0.790,
Figure 1d). Astrogliogenesis (which may include a small percen-
tage of neural progenitor cells) measured by the percentage of
BrdU+ cells co-labeled with GFAP was not signiﬁcantly altered by
stress exposure or administration of the different antipsychotic
drugs (Figures 1e and f).
To assess the role of CMS and antipsychotic drugs in cell
survival in the DG (long-term cell analysis), we analyzed the
number of BrdU+ cells that incorporated BrdU and survived after
4 weeks. CMS animals presented a decrease in cell survival in the
DG (F1,8 = 16.104; P= 0.004, Figure 2g). Regarding the action of
the different antipsychotics used, we observed no effect in the
haloperidol-treated group (P= 0.290, Figure 2g) and a beneﬁcial
effect promoted by the clozapine treatment (P= 0.018, Figure 2g)
with an increase in cell survival. These results are translated in
terms of neuronal survival assessed by the quantiﬁcation of the
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BrdU cells that express the neuronal marker NeuN (Figure 2h). As
previously described, we found a decrease in neuronal survival in
animals submitted to chronic stress (F1,8 = 7.684; P=0.024, Figure 2i).
Regarding the action of the different antipsychotics used, we
observed an overall effect of treatment (F1,12 = 5.338; P=0.022,
Figure 2i) with an increase in neuronal survival promoted by
clozapine (P=0.021, Figure 2i). No effect was observed in animals
chronically treated with haloperidol (P=0.666, Figure 2i).
Structural analysis
The three-dimensional morphometric analysis of Golgi-
impregnated neurons in the dentate gyrus revealed that exposure
to CMS-induced atrophy in granule neurons of the DG, with a
signiﬁcant decrease in their total dendritic length (F1,10 = 11,358;
P= 0.007, Figures 3a and b). Only clozapine treatment reversed
this structural change (P= 0.003, Figure 3a). Sholl analysis revealed
no statistical signiﬁcant differences between the experimental
groups (Figures 3c and d).
Signiﬁcant dendritic atrophy in total dendritic length was also
observed in pyramidal neurons in the PFC with CMS-exposed
animals presenting shorter neurons (F1,10 = 17.960; P= 0.002,
Figures 3e and f); this atrophic effect of chronic stress was
reversed by treatment with clozapine (P= 0.002, Figure 3e) but not
by haloperidol (P= 0.920, Figure 3e) treatment. In addition, Sholl
analysis revealed less complex neurons in CMS-exposed animals
when compared with controls (F1,10 = 7.871; P= 0.019, Figures 3g
and h). The effect of CMS was normalized by clozapine (P= 0.017,
Figure 3h) but not by haloperidol (P= 0.233, Figure 3h) treatment.
Gene expression studies
We analyzed the expression of different genes described to be
involved in neuronal plasticity in the hippocampus and in the PFC.
Figure 2. Antipsychotic treatment effects on the newly born cells and neuronal survival. (a) Proliferative niche of BrdU-labeled cells in the
subgranular zone (SGZ) obtained with optical microscope. (b) The density of BrdU-labeled cells in the SGZ of the dentate gyrus. (c) Niche of
newly formed neurons in the SGZ, obtained by confocal microscopy. (d) The percentage of BrdU+ cells that were co-labeled with the antibody
against PSA-NCAM. (e) Newly formed glial cells in the SGZ, obtained by confocal microscope. (f) Percentage of BrdU+ cells that were co-
labeled with glial marker GFAP in the SGZ. (g) The density of BrdU-labeled cells in the dentate gyrus that survives after 4 weeks. (h) Newly
formed neurons in the dentate gyrus that survives after 4 weeks. (i) The percentage of BrdU+ cells that were co-labeled with the antibody
against NeuN. (a–f) Short-term and (g–i) long-term effects of antipsychotics on neuro- and gliogenesis. Data represented as mean+s.e.m.
#Denotes the effect of CMS-exposure; *denotes the effect of antipsychotic compared with CMS non-treated animals.#,*Po0.05; **Po0.01;
***Po0.001. n= 5 animals per group. CMS, chronic mild stress; DG, dentate gyrus.
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The expression of BDNF was signiﬁcantly reduced in the
hippocampus of CMS rats (F1,8 = 5.510, P= 0.047, Figure 4a).
Chronic treatment with both antipsychotics was not able to
restore the expression of this gene to control levels (Figure 4a). We
found no signiﬁcant statistical differences in the expression of
NCAM1 and SYN1 in CMS animals (Figures 4b and c), and the
chronic treatment with haloperidol and clozapine did not alter
their expression (Figures 4b and c).
Figure 3. Three-dimensional morphometric analysis of Golgi-impregnated neurons using computer-assisted reconstructions of dentate gyrus
and prefrontal cortex (PFC). (a) Total dendritic length of neurons in the dentate gyrus of the hippocampus. (b) Representative neurons of
different experimental groups. (c) Representative sholl dendritic analysis of a dentate gyrus neuron, dendritic density was measured by
placing a series of concentric circles, spaced at 20 μm intervals centered on the soma. (d) Sholl analysis of dendritic distribution of neurons in
the dentate gyrus. (e) Total dendritic length of neurons in the PFC. (f) Representative neurons of different experimental groups. (g)
Representative sholl dendritic analysis of a PFC neuron, dendritic density was measured by placing a series of concentric circles, spaced at
20 μm intervals centered on the soma. (h) Sholl analysis of dendritic distribution of neurons in the PFC. Data represented as mean+s.e.m.
#Denotes the effect of chronic mild stress (CMS)-exposure; *denotes the effect of antipsychotic compared with CMS non-treated animals.
#,*Po0.05; ##,**Po0.01; ***Po0.001. n= 6 animals per group.
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Moreover, animals exposed to CMS revealed signiﬁcantly
reduced levels of BDNF (F1,8 = 29.305; P= 0.001, Figure 4d), NCAM1
(F1,8 = 17.184; P= 0.003, Figure 4e) and SYN1 (F1,8 = 18.336;
P= 0.003, Figure 4f) in the PFC. Treatment with clozapine was
able to promote an increase in the expression of BDNF (P= 0.027,
Figure 4d), NCAM1 (P= 0.048, Figure 4f) and SYN1 (P= 0.031,
Figure 4g), whereas the treatment with haloperidol revealed a
non-signiﬁcant increase in the gene expression of BDNF
(Figure 4d). We also analyzed the gene expression of different
dopamine receptors in the PFC (Figures 4g–i). We found Drd2
mRNA levels to be decreased in stressed animals (F1,8 = 6.512;
P= 0.034, Figure 4h), with no differences in Drd1 and Drd3. Only
clozapine treatment was able to restore the gene expression of
Drd2 (P= 0.019, Figure 4h).
DISCUSSION
Antipsychotic drugs have been generally classiﬁed into two
distinct pharmacological classes: the classical and the atypical
antipsychotics. The classical haloperidol acts as a D2 antagonist
with high afﬁnity for the receptors. Clozapine, as an atypical
antipsychotic drug, exhibits lower afﬁnity for D2 receptors and
displays multiple modulating actions, namely in serotonin and
noradrenaline receptors.13 Herein, we show that different classes
of antipsychotics have different effects on adult neuroplasticity,
namely on the process of adult hippocampal neurogenesis and
neuronal morphology. More so, we found that only clozapine-
treated animals, which presented a rescue in neuroplasticity, were
able to recover from the depressive-like phenotype and from the
cognitive deﬁcits in behavioral ﬂexibility induced by exposure to
Figure 4. Gene expression analysis of the hippocampus and prefrontal cortex (PFC) by RT-PCR. In the hippocampus, we measure the gene
expression levels of different neuroplastic markers such as (a) brain-derived neurotrophic factor (BDNF) (b) Ncam1 and (c) Syn1. The same
markers of neuroplasticity were measure in the PFC (d) BDNF (e) Ncam1 and (f) Syn1. In the PFC, the levels of expression of different dopamine
receptors (Dr) D1, D2, and D3 (g) Drd1, (h) Drd2 and (i) Drd3. Data represented as mean+s.e.m. #Denotes the effect of chronic mild stress
(CMS)-exposure; *denotes the effect of antipsychotic compared with CMS non-treated animals. #,*Po0.05; ##,**Po0.01; ###Po0.001. n= 5
animals per group.
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CMS. Contrarily, haloperidol-treated animals showed impairments
in neuroplasticity, presenting important deﬁcits in emotional and
cognitive behavior.
It is now clear that various forms of structural plasticity,
including the generation of new neurons and glial cells, may
modify the pathophysiology of some neuropsychiatric
disorders.15,20,26 This idea has been widely explored in depression.
In fact, multiple studies have shown a decrease in hippocampal
neurogenesis in animal models of depression, whereas treatment
with different antidepressants increases neurogenesis in this
region.14–16 Considering that atypical antipsychotics can be
effective in the treatment of refractory depression,7 we hypothe-
sized that these drugs may also regulate neuronal plasticity, in
which neurogenesis is included. Our data is in accordance with
this hypothesis; we observed that chronic treatment with
clozapine is able to promote an increase in neurogenesis and
that this effect persists even after the end of the treatment, with
clozapine-treated animals presenting an increased neuronal
survival. In contrast, the number of newly born cells and the
number of surviving neurons were negatively affected by the
chronic treatment with haloperidol. The same effect was
described by Maeda et al.29 in an animal model of schizophrenia
with impairments in adult neurogenesis. However, literature is not
consensual regarding this topic with signiﬁcant discrepancies
regarding the effects of haloperidol in neuroplasticity.14,30–32
These conﬂicting results might be due to differences in experi-
mental designs, drug dosages and the species studied. Another
possible explanation for these discrepancies is the use of control
animals to test these drugs, in which there are no prior deﬁcits in
behavior or in the levels of neurogenesis.30,33 Our present results
clearly demonstrate an opposite action of these classes of
antipsychotic drugs on adult neurogenesis without affecting the
glial cell lineage.
Previous studies from our lab have demonstrated the impor-
tance of structural changes in the hippocampus and PFC in the
pathophysiology of depression.18,22,26 Antidepressants drugs,
independent of their mechanism of action, are able to restore
these alterations.22 On the basis of these observations, it became
critical to understand the impact of antipsychotic drugs in this
type of event. In the present study, animals exposed to CMS
presented a decrease in the dendritic length in hippocampal
granule neurons; importantly, treatment with clozapine, but not
haloperidol, was able to reverse this effect. In the PFC, exposure to
CMS induced a decrease in total dendritic length and in neuronal
complexity; again, only clozapine was able to promote a
signiﬁcant recovery. Our observations are consistent with clinical
data suggesting that the structural changes observed in schizo-
phrenia can be attenuated by atypical antipsychotics.34 Further-
more, previous studies have demonstrated that treatment with an
atypical (olanzapine), but not a classical (haloperidol), antipsycho-
tic reversed dopamine denervation-induced changes in dendritic
length in the PFC.35 The present results clearly demonstrate the
different impact of classic and atypical antipsychotics in neuronal
remodeling in the hippocampus and PFC. This is in accordance
with our previous study describing neuronal remodeling as an
important neuroplastic event for the mood-improving actions of
antidepressants.22
In addition, we analyzed the expression of neuroplasticity-
related genes, such as Syn1, NCAM1 and BDNF in the
hippocampus and PFC. We observed a decrease in the expression
of these genes in the PFC of animals exposed to CMS, but also that
chronic treatment with clozapine was able to promote a recovery
in gene expression, thereby supporting the neuroplastic effects of
this drug. Interestingly, we found that animals with a decrease in
the expression of neuroplasticity-related genes presented deﬁcits
in a cognitive task depend (reversed learning task) on this brain
region. We also analyzed the possible modulation of the different
dopamine receptors namely Drd1, Drd2 and Drd3 in the PFC.
Indeed, CMS-exposure induced a signiﬁcant decrease in Drd2
receptor expression, whereas the atypical antipsychotic clozapine
was able to reverse this effect. These results are in accordance
with previous studies that have shown that clozapine exerts its
therapeutic effects in part by increasing dopaminergic neuro-
transmission in the PFC, whereas haloperidol had no signiﬁcant
effects on the cortical release of dopamine.36
Antipsychotic medications are the most commonly prescribed
drugs to treat schizophrenia. In 2006, Reif et al.37 found a
signiﬁcant reduction in hippocampal neural stem cell proliferation
in schizophrenic patients. Moreover, dendritic changes in frontal
cortical pyramidal cells are amongst one of the most replicated
ﬁndings in post-mortem studies of schizophrenia.38–41 These
studies highlight the role of neuroplasticity on schizophrenia. Our
present results demonstrate a beneﬁcial effect on adult neuro-
plasticity with chronic treatment with the atypical antipsychotic
clozapine. This effect could be one of the possible mechanisms
that may contribute to the action of atypical antipsychotics not
only in the positive symptoms of schizophrenia but also in the
negative and cognitive symptoms. In contrast, the efﬁcacy of
haloperidol treatment is mainly against the positive symptoms of
schizophrenia, exacerbating the negative and cognitive symp-
toms. Interestingly, our results clearly indicate the absence of a
positive effect on adult neuroplasticity after haloperidol treatment.
Despite the diverse pharmacological proﬁles (monoamine
oxidase inhibitors, tricyclic antidepressants, serotonin-selective
reuptake inhibitors and serotonin–norepinephrine reuptake inhi-
bitors), all antidepressant drugs result in similar behavioral and
neuroplastic outcomes, suggesting similar mechanisms of action.
In contrast, classical and atypical antipsychotics are strikingly
different as evidenced by their actions, mechanisms, effects and
side effects. For instance, the atypical antipsychotic clozapine has
a more complex pharmacological length proﬁle than the classical
haloperidol, presenting binding afﬁnities for various neurotrans-
mitter receptors, including several serotonin and noradrenaline
receptors.42 Furthermore, the effects of clozapine in feeding
behavior and body weight gain could be involved in the results
observed in the sucrose preference test. However, the positive
effects of this antipsychotic in the FST supports its mood-
improving effects. Thus, our present results suggest the potential
importance of serotonergic and noradrenergic system modulation
in the beneﬁcial effects of atypical antipsychotics on neuroplas-
ticity that should be addressed in future studies.
In conclusion, the present study demonstrates the modulation
of adult neuroplasticity by antipsychotics, revealing that the
atypical antipsychotic drug clozapine reverts the behavioral
effects of chronic stress while improving adult neurogenesis, cell
survival and neuronal reorganization. These observations may
pave the way to new therapeutic interventions not only in
treatment-resistant depression but also in schizophrenia.
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